tbuckley/cabot-search huggingface dataset:
43O Preoperative chemotherapy prior to primary tumor resection for colorectal cancer patients with asymptomatic resectable primary lesion and synchronous unresectable liver-limited metastases (RECUT): A prospective, randomized, controlled, multicenter clinical trial
Authors: Q. Lin, K. Ding, R. Zhao, H. Wang, L. Ren, Y. Wei, Q. Ye, Y. Cui, G. He, W. Tang, Q. Feng, D. Zhu, W. Chang, Y. Lv, Y. Mao, X. Wang, L. Liang, G. Zhou, F. Liang, J. Xu
Journal: Annals of Oncology (2022)
45MO Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort
Authors: Y. Kuboki, R. Yaeger, M. Fakih, J.H. Strickler, T. Masuishi, E.J-H. Kim, C.M. Bestvina, C.J. Langer, J.C. Krauss, S. Puri, P. Cardona, E.K. Chang, Q. Tran, D.S. Hong
Journal: Annals of Oncology (2022)
281P Cancer-related symptoms as mediators between treatment and functional capacity in adolescents and young adults (AYAs) with cancer
Authors: C.T.J. Ma, H.H.F. Loong, W.T. Ip, J. Zhang, A.W.K. Leung, C.K. Ngan, C-K. Li, C. Yin Ting
Journal: Annals of Oncology (2022)
174TiP SPARKLE: A new spark in treating oligorecurrent prostate cancer: Adding systemic treatment to stereotactic body radiotherapy or metastasectomy: Key to long-lasting event-free survival?
Authors: K. Rans, C. Berghen, S. Joniau, A. Laenen, K. Poels, K. Goffin, H. Dumez, K.M. Haustermans, G. De Meerleer
Journal: Annals of Oncology (2022)
387P Telisotuzumab vedotin (Teliso-V) in combination with osimertinib in patients with advanced EGFR-mutated, c-met overexpressing, non-small cell lung cancer (NSCLC): Safety and efficacy results from phase Ib study
Authors: H. Horinouchi, J.W. Goldman, B.C. Cho, P. Tomasini, M. Dunbar, D. Hoffman, A. Parikh, V. Blot, D.R. Camidge
Journal: Annals of Oncology (2022)
165P Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Authors: R. Kelly, S.S.L. Wong, J. Shapiro, A.J. Weickhardt, P. Parente, A. Azad, A. Uccellini, J. Torres, F. Parnis, E. Kwan, S. Brown, C. Steer, M. Warren, P. Gibbs, A. Anton, B. Tran
Journal: Annals of Oncology (2022)
51P Efficacy and safety of sintilimab as first-line therapy in patients with microsatellite instability-high metastatic colorectal cancer: A real-world study
Authors: C. Nie, W. Xu, H. Lv, B. Chen, J. Wang, Y. Liu, J. Zhao, Y. He, S. Wang, X. Chen
Journal: Annals of Oncology (2022)
104P A multi-institutional epidemiological and oncological profile of gastrointestinal stromal tumors in the Lebanese population
Authors: M.H. El Charif, E. Sbaity, M.A.F. Salloum, N. Maanieh, A. Hoteit, I. Al Mohtar, M.J. Khalifeh, H. Assi, F.S.S. Farhat
Journal: Annals of Oncology (2022)
440P Targeting KRASG12C: Repurposing of potential therapeutics for the treatment of pancreatic ductal adenocarcinoma (PDAC)
Authors: E.R. Kabir, M. Haque Tanisha, B. Hossain Sagar, R. Mollika, T.T.S. Khan, N.M. Chowdhury, H. Yasmin, N.Z. Khair, M. Quadir, N. Mustafa
Journal: Annals of Oncology (2022)
305MO SCC244 plus osimertinib in patients with stage IIIB/IIIC or IV, EGFR TKI resistant EGFR-mutant NSCLC harboring MET amplification
Authors: Y. Yu, N. Yang, Y. Zhang, H. Zhang, M. Li, Q. Yu, J. Zhou, X. Hu, J. Fang, H. Zhao, J. Feng, L. Li, Y. Shu, X. Wang, M. Sun, J. Zhang, M. Li, Y. Ren, S. Lu
Journal: Annals of Oncology (2022)
358P Intracranial metastatic disease (IMD) burden and management of patients with small cell lung cancer (SCLC): A population-based analysis of 8705 patients
Authors: K. Gaebe, A.W. Erickson, A. Li, N. Leighl, K.K. Chan, S. Habbous, B. Lok, S. Das
Journal: Annals of Oncology (2022)
320MO Envonalkib vs crizotinib in treatment-naïve advanced ALK-positive NSCLC: A randomized, multicenter, phase III trial
Authors: L. Zhang, W. Fang, J. Min, N. Yang, Q. Yu, Y. Cheng, Y. Zhao, M. Li, H. Chen, S. Ren, J. Zhou, W. Zhuang, X. Qin, L. Cao, Y. Yu, J. Zhang, J. He, J. Feng, H. Yu
Journal: Annals of Oncology (2022)
343P Immunotherapy as first-line treatment in metastatic non-small cell lung cancer: A single center experience
Authors: H. N.J, A. Rauthan, P. Patil, K. Lahkar, N.Y. Murthy, P. Vundemodalu, R. Ashwath, C. Jomi, P. S N
Journal: Annals of Oncology (2022)
220O RATIONALE-309: Effects of tislelizumab on health-related quality of life (HRQoL) in patients with recurrent or metastatic nasopharyngeal cancer (R/M NPC)
Authors: Y. Yang, J. Pan, N. Chen, Y. Wu, S. Leaw, F. Bai, Y. Wang, N. Zhao, B. Tang, G. Barnes
Journal: Annals of Oncology (2022)
LBA6 Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer: A multicentre, open-label, randomized phase III study
Authors: S. Lu, J. Zhou, H. Jian, L. Wu, Y. Cheng, Y. Fan, J. Fang, G. Chen, Z. Zhang, D. Lv, L. Jiang, R. Wu, X. Jin, X. Zhang, J. Zhang, G. Sun, D. Huang, J. Cui, R. Guo, L. Ding
Journal: Annals of Oncology (2022)
153P Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
Authors: T.C.D. Padua, L. Marandino, D. Raggi, A. Briganti, F. Montorsi, A. Necchi
Journal: Annals of Oncology (2022)
330P A real-world multi-center prospective observational study of atezolizumab (Atezo) + bevacizumab (Bev) + carboplatin (CBDCA) + paclitaxel (PTX) (ABCP) in patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC after EGFR-TKIs failure
Authors: S. Kuyama, H. Yoshioka, H. Kaneda, Y. Kataoka, S. Miura, N. Katakami, Y. Yamanaka, A. Tamiya, T. Yamada, T. Yokoyama, S. Hara, H. Tanaka, Y. Fujisaka, A. Nakamura, K. Azuma, M. Namba, A. Hata, K. Sawa, H. Ishikawa, T. Kurata
Journal: Annals of Oncology (2022)
LBA4 CANOPY-N: A phase II study of canakinumab (CAN) or pembrolizumab (PEM), alone or in combination, as neoadjuvant therapy in patients (pts) with resectable stage Ib–IIIa non-small cell lung cancer (NSCLC)
Authors: T.S.K. Mok, J-L. Pujol, M. Tsuboi, J. Lee, E. Kim, O. Leonov, J. Zhang, J. Duan, C. Lobetti-Bodoni, J.C. Brase, A. Savchenko, P. Garrido Lopez
Journal: Annals of Oncology (2022)
359P Epidermal growth factor receptor (EGFR) mutation testing and immunotherapy (IO) use associated with diagnosis of non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions (ex20ins) in the US
Authors: S-H.I. Ou, M. Lin, Y. Yin, E. Curran, E. Churchill, Z. Piotrowska
Journal: Annals of Oncology (2022)
141P Real-world study of cabozantinib treatment of advanced renal cell carcinoma in Taiwan
Authors: Y-C. Tsai, J-R. Li, P.J. Su, Y-L. Su, H-J. Chung, C-C. Li, C-P. Huang, J-C. Guo, C-S. Chen, E. Wang, V. Perrot, Y.H. Chang
Journal: Annals of Oncology (2022)
74MO HERIZON overall survival results: A study of IMU-131, a HER2 targeting peptide vaccine, plus standard of care chemotherapy in patients with HER2 overexpressing metastatic or advanced gastric/GEJ cancer
Authors: M. Maglakelidze, D. Ryspayeva, Z.G. Andric, Z. Petrovic, I.V. Bulat, I.V. Nikolic, T. Chawla, R. Nagarkar, U. Wiedermann, B.A. Blumenstein, L.M.O. Chong, N.J. Ede, B. Nixon, A.J. Good
Journal: Annals of Oncology (2022)
52P HGCSG1901: A retrospective cohort study evaluating the safety and efficacy of S-1 and irinotecan plus bevacizumab in patients with metastatic colorectal cancer - Impact of single-heterozygous UGT1A1 on the clinical outcomes
Authors: S. Yuki, K. Ito, K. Harada, Y. Kawamoto, M. Yagisawa, K. Sawada, A. Ishiguro, O. Muto, K. Hatanaka, H. Okuda, A. Sato, Y. Sasaki, M. Nakamura, T. Meguro, M. Dazai, H. Nakatsumi, A. Ueda, N. Sakamoto, Y. Sakata, Y. Komatsu
Journal: Annals of Oncology (2022)
157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Authors: M. Oya, A.J. Armstrong, A. Thiery-Vuillemin, N. Shore, G. Procopio, Ç. Arslan, N. Mehra, F. Parnis, E. Brown, F. Constans Schlurmann, J.Y. Joung, M. Sugimoto, O. Sartor, Y-Z. Liu, C.H. Poehlein, C. Desai, P.M.D. Del Rosario, N. Clarke, F. Saad
Journal: Annals of Oncology (2022)
136MO Efficacy and safety of pembrolizumab (pembro) monotherapy in East Asian patients (pts) with urothelial carcinoma (UC) in KEYNOTE-045 or KEYNOTE-052
Authors: J-L. Lee, B. Keam, R. Kanesvaran, Y. Yamamoto, W-P. Su, P-H. Chiang, C-C. Lin, N. Sassa, K. Nishimura, K. Fujimoto, P.M-H. Chang, M. Kim, S. Fukasawa, M. Yokoyama, H. Enokida, J. Xu, B. Homet Moreno, K. Imai, H. Nishiyama, S.Y. Rha
Journal: Annals of Oncology (2022)
407P A post-marketing surveillance of the real-world safety and effectiveness of avelumab in patients with curatively unresectable Merkel cell carcinoma in Japan
Authors: N. Yamazaki, Y. Kiyohara, M. Sato, S. Endo, B. Song, Y. Tanaka, A. Kambe, Y. Sato, H. Uhara
Journal: Annals of Oncology (2022)
317P A project to investigate the actual status of biomarker testing in unresectable advanced or recurrent non-small cell lung cancer: WJOG15421 L (REVEAL)
Authors: T. Matsubara, T. Sakamoto, T. Takahama, S. Ikeda, None M. mori, C. Mimura, H. Kodama, K. Maeno, S. Miura, T. Harada, T. Sawa, T. Miyawaki, N. Kanaji, None K. nishimura, M. Hiraoka, H. Kenmotsu, J. Fujimoto, M. Shimokawa, N. Yamamoto, K. Nakagawa
Journal: Annals of Oncology (2022)
LBA7 A randomized, double-blind, multinational phase III study to assess the efficacy and safety of lazertinib versus gefitinib in the first-line treatment of patients with EGFR mutation (EGFRm), advanced NSCLC (LASER301; NCT04248829)
Authors: B.C. Cho, M-J. Ahn, J.H. Kang, R. Soo, T. Baisamut (Reungwetwattana), J.C-H. Yang, I. Cicin, D-W. Kim, Y-L. Wu, S. Lu, K. Lee, Y-K. Pang, A. Zimina, C.H. Fong, E. Poddubskaya, Y. Kim, T. An, H. Lee, H. Byun, B. Zaric
Journal: Annals of Oncology (2022)
187P BUB1 (2530C&gt;T) polymorphism and expression affects chemotherapy response and predicts poor prognosis in advanced epithelial ovarian cancer
Authors: S. Sarkar, P.K. Sahoo, T. Mistry, R. Pal, S. Ghosh, T. Choudhury, S. Mahata, M. Vernekar, T. Bera, K.K. Mukherjee, P. Nath, V.D. Nasare
Journal: Annals of Oncology (2022)
221O Induction chemotherapy regimen of docetaxel plus cisplatin vs docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of a phase III multicenter randomized controlled trial
Authors: S. He, Y. Wang, C. Wang, Z. Peng, Y. Chen
Journal: Annals of Oncology (2022)
363P A multicentre, real-world observational study of efficacy and safety of first-line osimertinib treatment in patients with epidermal growth factor receptor (EGFR) activating mutation-positive advanced non-small cell lung cancer (Reiwa study)
Authors: T. Fukui, K. Naoki, K. Yoh, K. Usui, Y. Hosomi, K. Kishi, G. Naka, K. Watanabe, K. Uemura, H. Kunitoh
Journal: Annals of Oncology (2022)
134TiP A phase I/II study of nanoliposomal irinotecan plus S-1 in metastatic pancreatic cancer after first-line gemcitabine-based chemotherapy
Authors: H. Imaoka, M. Sasaki, M. Ueno, M. Ozaka, S. Kobayashi, T. Fukushima, T. Furukawa, M. Ikeda
Journal: Annals of Oncology (2022)
411P Cost-effective analysis of the various cancer screening methods in the community: Pooled analysis of camps of 5 years from 2017-to 2022
Authors: S.V.S. Attili, R. Sharma, S. Peri, M. Singaraju, P.K. Dadireddy, P.K.R. Kistampally
Journal: Annals of Oncology (2022)
132TiP Dose escalation of chemoradiotherapy in locally advanced esophageal squamous cell carcinoma based on positron emission tomography response: A phase III, open-label, randomized, controlled trial (ESO-Shanghai 12)
Authors: H. Zhu, Q. Liu, H. Xu, M. Mo, Z. Wang, K. Lu, J. Zhou, J. Chen, X. Zheng, J. Ye, X. Ge, H. Luo, S. Song, Y. Chen, K. Zhao
Journal: Annals of Oncology (2022)
421P The association between early changes in neutrophil-lymphocyte ratio and survival in patients treated with immunotherapy
Authors: D.C. Guven, T.K. Sahin, E. Erul, I.Y. Cakir, E. Ucgul, H.C. Yildirim, O.H. Aktepe, M. Erman, S. Kilickap, S. Aksoy, S. Yalcin
Journal: Annals of Oncology (2022)
216P Lenalidomide maintenance after whole brain radiotherapy in relapsed/refractory primary CNS lymphoma
Authors: B. Bagal, J. Goda Shastri, L. Nayak, A. Chatterjee, A. Dasgupta, H. Jain, J. Thorat, A. Sahay, S. Epari, N. Khanna, S. Laskar, T. Gupta, M. Sengar
Journal: Annals of Oncology (2022)
265P Tumor-agonistic genomic profiling
Authors: N. Hayashi, I. Fukada, A. Ohmoto, M. Hosonaga, X. Wang, M. Yamazaki, A. Ueki, K. Kiyotani, A. Tonooka, K. Takeuchi, S. Mori, S. Takahashi
Journal: Annals of Oncology (2022)
LBA12 Tumour genomics in patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib in the phase II ELIOS study
Authors: M-J. Ahn, B.C. Cho, Y.K. Pang, P.J. Voon, S-W. Kim, J. De Castro Carpeno, M. Tiseo, J. Li, L. Servidio, S. Sadow, A. Markovets, K.H. Tang, Z. Piotrowska
Journal: Annals of Oncology (2022)
177O Lenvatinib plus pembrolizumab versus treatment of physician’s choice in patients with previously treated advanced endometrial cancer: Study 309/KEYNOTE-775 Asian subgroup
Authors: K. Yonemori, K. Fujiwara, K. Hasegawa, M. Yunokawa, K. Ushijima, S. Suzuki, A. Shikama, S. Minobe, T. Usami, J-W. Kim, B-G. Kim, P-H. Wang, T-C. Chang, K. Yamamoto, S. Han, J. McKenzie, G. Barresi, T. Miura, V. Makker, Y.M. Kim
Journal: Annals of Oncology (2022)
346P The safety and efficacy of intrathecal chemotherapy with pemetrexed via the Ommaya reservoir for leptomeningeal metastases from lung adenocarcinoma: A prospective study
Authors: H. Li, Y. Lin, T. Yu, Y. Xie, C. Jiang, J. Feng, X. Qian, Z. Yin
Journal: Annals of Oncology (2022)
75MO Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): Results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6
Authors: Z.A. Wainberg, P.C. Enzinger, S. Qin, K. Yamaguchi, A. Gnanasakthy, K. Taylor, A. Jamotte, I. Majer, Y-K. Kang
Journal: Annals of Oncology (2022)
368P A special Imaging pattern of bilateral diffuse metastases in advanced lung adenocarcinoma harboring EGFR mutations was associated with a favorable prognosis to EGFR-TKIs
Authors: Z-B. Gu, J-L. Zhao, C. Luo, A-W. Liu, L. Huang, Y-L. Lv, H-Y. Huang
Journal: Annals of Oncology (2022)
99P Impact of single-heterozygous UGT1A1 on the clinical outcomes of nano-liposomal irinotecan plus 5-fluorouracil/leucovorin for patients with pancreatic ductal adenocarcinoma
Authors: K. Harada, T. Yamamura, O. Muto, M. Nakamura, S. Sogabe, K. Sawada, S. Nakano, M. Yagisawa, T. Muranaka, M. Dazai, M. Tateyama, Y. Kobayashi, S. Kato, T. Miyagishima, Y. Kawamoto, S. Yuki, Y. Sakata, N. Sakamoto, Y. Komatsu
Journal: Annals of Oncology (2022)
225MO Clinical, pathologic and immune-related features of radiation-associated oral cavity squamous cell carcinoma: A matched cohort study
Authors: J.C-H. Chow, W. Cheuk, D.W.Y. Au, C.F. Wong, A.H.P. Tam, K.M. Cheung, J.C.H. Chan, C.C. Law, K.C.R. Ngan, K.H. Wong, C.W. Wong, W.C.S. Cho
Journal: Annals of Oncology (2022)
LBA10 A multicenter, randomized, double-blind, phase III study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER)
Authors: L. Zhang, W. Fang, Q. Yu, H. Zhang, G. Wu, D. Wu, Y. Lin, J. Zhu, J. Chen, X. Hu, B. Lan, Z. Zhou, H. Lin, Z. Wang, X. Lei, S. Pan, L. Chen, J. Zhang, T. Kong, H. Yu
Journal: Annals of Oncology (2022)
179O A phase II, open-label, single-arm study of QL1604 plus paclitaxel-cisplatin/carboplatin as first-line treatment in patients with recurrent or metastatic cervical cancer
Authors: J. Liu, C. Fang, Q. Zhou, L. He, J. Yu, Y. Li, M. Feng, M. Pan, L. Zhao, D. Tang, X. Li, B. Tan, R. An, X. Zheng, M. Si, B. Zhang, L. Li, X. Kang
Journal: Annals of Oncology (2022)
362P Intracranial activity of dacomitinib in treatment naïve advanced EGFR mutated non-small cell lung cancer (NSCLC): Prespecified subgroup analysis of the ATORG-003 trial
Authors: A. Tan, D-W. Kim, T. Baisamut (Reungwetwattana), L. Yueh Ni, G.F. Ho, L.M. Tho, N. Prasongsook, S. Lee, T.S.K. Mok, D.S.W. Tan, H.H.F. Loong
Journal: Annals of Oncology (2022)
133TiP An open label pilot study to evaluate efficacy and safety of durvalumab with hepatic artery infusion chemotherapy (HAIC) in advanced hepatocellular (aHCC) patients with severe portal vein tumor thrombosis (PVTT) (Vp3 and/or Vp4): DurHope
Authors: M. Zhao, X. Wang, N. Lyu, Q. Chen, X. Jiang, Y. Hu, M. He, J. Lai
Journal: Annals of Oncology (2022)
347P Real-world efficacy of first-line therapy in wild-type non-small cell lung cancer (NSCLC) patients with brain metastases
Authors: B. Kong, J. Wei, S. Smith, W.Y. Chan, S.V. Harden, V. Khou, M. Alexander, C. Brown, M. Itchins, J. Lee, A. Mersiades, L. Gray, M. Boyer, N. Pavlakis, S. Clarke, D. Jayamanne, S.C-H. Kao
Journal: Annals of Oncology (2022)
322MO Amivantamab in combination with lazertinib in patients with atypical epidermal growth factor receptor (EGFR) mutations excluding exon 20 insertion mutations: Initial results from CHRYSALIS-2
Authors: B.C. Cho, Y. Wang, Y. Li, L. Wu, B. Besse, M.E. Marmarelis, K. Goto, J-S. Lee, S-H. Lee, Y. Zhang, J. Neal, J. Curtin, J.M. Bauml, J. Mahoney, L. Trani, R.E. Knoblauch, P. Tomasini
Journal: Annals of Oncology (2022)
398TiP MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy vs chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure
Authors: J. Wang, R. Garcia Campelo, N. Girard, N. Leighl, K. Reckamp, T. Takahashi, S. Li, D. Millington, P. Barala, J.M. Bauml, R.E. Knoblauch, B.C. Cho
Journal: Annals of Oncology (2022)
267P Genomic landscape of non-small cell lung cancer (NSCLC) in India using circulating tumor DNA (ctDNA) in clinical practice
Authors: A. Rauthan, K. Prabhash, N. Rohatgi, R. Thirumalairaj, A. Agarwal, S.S. P, S. Limaye, U. Batra, N. Raizada, P. Patil, S. Dattatreya Palanki, B. Sirohi, A. Dhar, A.K. Mukherjee, N. Joshi, S. Olsen
Journal: Annals of Oncology (2022)
319O ALTA-3: A randomized trial of brigatinib (BRG) vs alectinib (ALC) in crizotinib (CRZ)-refractory advanced ALK+ NSCLC
Authors: J.C-H. Yang, G. Liu, S. Lu, J. He, M. Burotto, S. Vincent, J. Yin, X. Ma, S. Popat
Journal: Annals of Oncology (2022)
201P Immunotherapy in advanced mismatch repair deficiency endometrial cancer: A real-world single center experience
Authors: A. Rauthan, N.Y. Murthy, P. Patil, S. Sampige Prasannakumar, S. Zaveri, R. Ashwath, P. Vundemodalu, C. Jomi
Journal: Annals of Oncology (2022)
98P Nanoliposomal irinotecan with fluorouracil and folinic acid, S-1 alone, or FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer after gemcitabine plus nab-paclitaxel: A pooled analysis of NAPOLEON-1 and NAPOLEON-2
Authors: T. Otsuka, T. Shirakawa, M. Shimokawa, T. Shibuki, J. Nakazawa, S. Arima, K. Miwa, F. Koga, Y. Kubotsu, Y. Ueda, A. Hosokawa, S. Takeshita, H. Shimokawa, A. Komori, M. Kawahira, H. Oda, T. Sakai, S. Arita, T. Mizuta, K. Mitsugi
Journal: Annals of Oncology (2022)
166P Comparative assessment of prognostic outcomes between vintage hormonal therapy and androgen deprivation therapy combined with novel androgen pathway inhibitor in Japanese patients with metastatic castration-sensitive prostate cancer
Authors: K. Tamura, H. Watanabe, K. Nakane, K. Takahara, T. Naiki, T. Yasui, R. Shiroki, T. Koie, H. Miyake
Journal: Annals of Oncology (2022)
360P ELIOS: A multicentre, molecular profiling study of patients (pts) with epidermal growth factor receptor-mutated (EGFRm) advanced NSCLC treated with first-line (1L) osimertinib
Authors: Z. Piotrowska, M-J. Ahn, Y-K. Pang, S.H. How, K. Sang-We, P.J. Voon, D.L. Cortinovis, J. De Castro Carpeno, M. Tiseo, D. Rodriguez Abreu, S.S. Ramalingam, J. Li, L. Servidio, S. Sadow, R.J. Hartmaier, B.C. Cho
Journal: Annals of Oncology (2022)
23P Combination chemotherapy and hormone therapy (CHT) in patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): A single-centre retrospective analysis
Authors: K. Bajaj, D.N. Vora, P. Parab, H. Shaikh, S. Gulia, S. Rath, J. Bajpai, T. Shet, S. Desai, P. Popat, R. Rajan, N.S. Nair, S. Joshi, R. Pathak, R. Sarin, Y. Kembhavi, S. Rane, J. Ghosh, R.A. Badwe, S. Gupta
Journal: Annals of Oncology (2022)
385P Efficacy and safety of pyrotinib in untreated, advanced non-small cell lung cancer with HER2 mutations: A parallel, multi-center, multi-cohort patient-centric study (CTONG1702 and 1705)
Authors: S-Y.M. Liu, H-Y. Tu, X-W. Wei, H-H. Yan, X. Dong, J. Cui, Z. Zhou, C. Xu, M. Zheng, Y. Li, Z. Wang, Y. Du, Y. Chen, R. Ma, B. Wang, S. Cang, J-J. Yang, H. Chen, Q. Zhou, Y-L. Wu
Journal: Annals of Oncology (2022)
3MO Patient-reported outcomes (PROs) of Chinese patients (pts) in monarchE: Abemaciclib plus endocrine therapy (ET) in adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (EBC)
Authors: Q. Zhang, K. Shen, C. Song, Q. Ouyang, Z. Liu, Q. Liu, X. Wang, Y. Yang, C. Qian, Z. Shao
Journal: Annals of Oncology (2022)
227MO Characterization of minimal residual disease (MRD) post-radiotherapy (RT) in nasopharyngeal carcinoma (NPC) patients identifies a favorable subgroup with low risk of relapse
Authors: J. Neo, E. Ong, A. Sim, J.J. Miao, J.T.S. Wee, K.W. Fong, Y.L. Soong, S.Y. Sin, D.S.W. Tan, D.W-T. Lim, M-K. Ang, M.L.K. Chua
Journal: Annals of Oncology (2022)
137MO Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Longer-term follow-up from the Asian subgroup of the JAVELIN Bladder 100 trial
Authors: M. Eto, C.J. Desai, S.H. Park, N. Tsuchiya, P.J. Su, T.W. Chan, H.P. Gurney, S. Gao, J. Wang, R. Sandner, A. di Pietro, J-L. Lee
Journal: Annals of Oncology (2022)
139MO Prognostic significance of the mechanism of inflammatory markers in advanced renal cell carcinoma patients treated with nivolumab plus ipilimumab
Authors: T. Nakayama, H. Takeshita, M. Kagawa, S. Washino, S. Shirotake, Y. Miura, Y. Hyodo, K. Izumi, M. Inoue, T. Miyagawa, M. Oyama, K. Saito, Y. Kageyama, S. Kawakami
Journal: Annals of Oncology (2022)
180O Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II study
Authors: X. Wu, L. Xia, J. Wang, C. Wang, Q. Zhang, J. Zhu, Q. Rao, H. Cheng, Z. Liu, Y. Yin, X. Ai, K. Gulina, H. Zheng, X. Luo, B. Chang, L. Li, H. Liu, Y. Li, J. Zhu
Journal: Annals of Oncology (2022)
158MO Niraparib with abiraterone acetate and prednisone (NIRA+AAP) as first-line therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR+) gene alterations: Asian subgroup analysis of the MAGNITUDE study
Authors: M. Binti Saad, K.N. Chi, W. Jung, S-T. Pang, G. Attard, S.K. Sandhu, G.E. Mason, A. del Corral, G. Wang, D. Wu, B. Diorio, A. Lopez-Gitlitz, J.Y. Lee
Journal: Annals of Oncology (2022)
271P Prospective study on toxicity profile of immunotherapy in a Indian population: A real-world experience
Authors: K.M. Ramegowda, A.N. Patel, H.P. Singh, A. Kapoor, S. Pandalanghat, D.S. Mulajker, A. Rathore, R.R. Nair, S.S. Mathighatta Shivarudraiah, D.M. Bhuva, A. Malviya, N. Sreenath, A. Mehrotra
Journal: Annals of Oncology (2022)
388P Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-R−), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study
Authors: Y-L. Wu, J. Zhao, J. Hu, J. Wu, Y. Xu, Z. Yang, Z. Liu, L. Jiang, J. Chen, Y. Yu, M. Huang, X. Dong, L. Liu, W. Feng, L. Wu, S. Cang, J. Sun, Q. Xie, H-J. Chen
Journal: Annals of Oncology (2022)
176O Final overall survival (OS) results from the phase III PAOLA-1/ENGOT-ov25 trial evaluating maintenance olaparib (ola) plus bevacizumab (bev) in patients (pts) with newly diagnosed advanced ovarian cancer (AOC)
Authors: S. Nagao, P. Harter, A. Leary, C. Cropet, S. Pignata, K. Fujiwara, A.J. Gonzalez Martin, G. Bogner, I. Vergote, N. Colombo, J. Maenpaa, F. Selle, B. Schmalfeldt, G. Scambia, E.M. Guerra Alia, C. Lefeuvre-Plesse, A. Belau, A. Lortholary, M. Gropp-Meier, E. Pujade-Lauraine, I. Ray-Coquard
Journal: Annals of Oncology (2022)